Aurinia Pharmaceuticals Inc.
AUPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.24 | 0.00 | 0.01 | -2.48 |
| FCF Yield | 2.93% | 3.75% | 0.11% | 2.35% |
| EV / EBITDA | 43.94 | 42.84 | 37.27 | 177.23 |
| Quality | ||||
| ROIC | 6.27% | 4.42% | 4.63% | -0.43% |
| Gross Margin | 88.42% | 89.84% | 86.27% | 90.73% |
| Cash Conversion Ratio | 1.41 | 2.06 | 0.06 | 21.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.72% | 17.55% | 18.98% | 20.61% |
| Free Cash Flow Growth | 0.55% | 3,340.61% | -95.73% | 77.40% |
| Safety | ||||
| Net Debt / EBITDA | 0.15 | 1.02 | 0.38 | -0.57 |
| Interest Coverage | 0.00 | 17.98 | 20.48 | -1.46 |
| Efficiency | ||||
| Inventory Turnover | 0.19 | 0.15 | 0.19 | 0.14 |
| Cash Conversion Cycle | 488.51 | 597.88 | 498.74 | 606.76 |